Doel van het onderzoek: The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for patients with advanced cancer. Everolimus is designed to stop cells from dividing. Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and spread of cancer. Denosumab is designed to block the activity of a protein, which may prevent bone complications in cancer that has spread to the bone.
Sponsor: M.D. Anderson Cancer Center
Contactgegevens voor de proefperiode: Veronica Holley; VRHolley@mdanderson.org Filip Janku; 713-563-1930; FJanku@mdanderson.org
Gewenste betrokkenheid van de patiënt: ECD patients at least 18 years of age. Patients may be BRAF positive or negative.
Bekende centra die ECD-patiënten in het onderzoek opnemen: MD Anderson, Houston, Texas
ClinicalTrials.gov-identificatiecode: NCT01624766